Based on these findings, it will be interesting to investigate whether specific targeting of Klf5 in pathological contexts, for example insulin resistance or type 2 diabetes, is sufficient to rectify lipotoxicity and improve lipid oxidation. The gene discussed is KLF5; the disease is type 2 diabetes mellitus.